Basic Information
TARLONIB 25 FILM COATED TABLET 25MG
TABLET, FILM COATED
Regulatory Information
SIN16238P
June 11, 2021
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
XL01EB02
Company Information
Active Ingredients
Strength: 25mg
Detailed Information
Contraindications
**CONTRAINDICATIONS** Erlotinib is contraindicated in patients with severe hypersensitivity to erlotinib or to any component of erlotinib.
Indication Information
**INDICATIONS** **Non-small cell lung cancer** Erlotinib is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations. Erlotinib is also indicated for switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy. Erlotinib is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-negative tumours. **Pancreatic cancer** Erlotinib in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.